Poland· PL-100457776
Abecma
A idecabtagene vicleucel product containing idecabtagenum vicleucelum, registered in Poland by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 10 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Idecabtagene vicleucel is registered in 10 of 19 countries.
Countries holding a registration under ATC L01XL07 (idecabtagene vicleucel), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Idecabtagene vicleucel · ATC L01XL07
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Idecabtagenum vicleucelum
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Poland (PL)
- ATC code
- L01XL07
- ATC class
- Idecabtagene vicleucel
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin08027950801800
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Idecabtagene vicleucel in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesAbecmaCelgene Corporation
- SwitzerlandAbecma Infusionsdispersion, von 260 bis 500 × 10e6 CAR-positiven lebensfähigen T-ZellenBristol-Myers Squibb SA
- CzechiaABECMABristol-Myers Squibb Pharma EEIG, Dublin
- SpainABECMA 260-500 x 10e6 CELULAS DISPERSION PARA PERFUSIONBristol-Myers Squibb Pharma Eeig
- FinlandAbecmaBristol-Myers Squibb Pharma EEIG
- BelgiumAbecma 260-500 x 10*6 cellsBristol-Myers Squibb Pharma
- IrelandAbecma 260 - 500 x 106 cells dispersion for infusionBristol-Myers Squibb Pharmaceuticals uc
- IcelandAbecmaBristol-Myers Squibb Pharma EEIG*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Abecma
- Liechtenstein · Abecma
- Norway · Abecma
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9af961c9-b478-4755-987e-95801a925142 GET /v1/drugs/9af961c9-b478-4755-987e-95801a925142?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Dyspersja do infuzji",
"source": "urpl",
"strength": "260 – 500 x 10^6 komórek",
"packaging": "08027950801800 ¦ Rpz ¦ EU/1/21/1539/001 ¦ 141904\n1 worek do 100 ml",
"substance": "Idecabtagenum vicleucelum 260 – 500 x 10^6 komórek",
"common_name": "Idecabtagenum vicleucelum",
"pl_product_id": "100457776",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about idecabtagene vicleucel.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.